The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials.
 
Aranzazu Fernandez-Martinez
No Relationships to Disclose
 
Mattia Rediti
No Relationships to Disclose
 
Gong Tang
No Relationships to Disclose
 
Tomas Pascual
No Relationships to Disclose
 
Katherine A. Hoadley
No Relationships to Disclose
 
David Venet
No Relationships to Disclose
 
Naim Rashid
No Relationships to Disclose
 
Patricia Spears
Consulting or Advisory Role - Pfizer; Pfizer
 
Md N. Islam
No Relationships to Disclose
 
Sarra El-Abed
Employment - argenx (I); Astellas Pharma (I)
Research Funding - Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Judith Bliss
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); GlaxoSmithKline/Novartis (Inst); Janssen-Cilag (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Matteo Lambertini
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
Speakers' Bureau - Ipsen; Knight Therapeutics; Libbs; Lilly; Novartis; Pfizer; Roche; Sandoz; Takeda
 
Jens Bodo Huober
Honoraria - Abbvie; AstraZeneca Japan; Celgene; Eisai; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Abbvie; AstraZeneca Japan; Celgene; Hexal; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - Celgene (Inst); Hexal (Inst); Lilly (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Celgene; Daiichi Sankyo; Novartis; Pfizer; Roche
 
David Goerlitz
No Relationships to Disclose
 
Rong Hu
No Relationships to Disclose
 
Peter C. Lucas
Stock and Other Ownership Interests - Amgen
Honoraria - Schrodinger (I)
 
Sandra M. Swain
Consulting or Advisory Role - AstraZeneca; Athenex; Beijing Medical Award Foundation; bioTheranostics; Daiichi Sankyo; Exact Sciences; Genentech/Roche; Inivata; Lilly; Merck; Molecular Templates; Natera; Silverback Therapeutics
Research Funding - Genentech (Inst); Kailos Genetics (Inst)
Other Relationship - AstraZeneca; Roche
 
Christos Sotiriou
Consulting or Advisory Role - Amgen; Amgen; Astellas Pharma; Astellas Pharma; CEPHEID; Merck; Puma Biotechnology; Seagen; Vertex
Speakers' Bureau - Eisai; Foundation Medicine; Genomic Health; Prime Oncology; Teva
Patents, Royalties, Other Intellectual Property - A companion diagnostic for CDK4/CDK6 inhibitory drugs based on CDK4 Phosphorylation. Which patient to be treated and how. PCT/EP2017/061780; Epigenetic portraits of human Breast Cancer, PCT/EP2012/050836, WO2012/098215
Travel, Accommodations, Expenses - Roche; Roche/Genentech; Roche/Genentech
 
Charles M. Perou
Leadership - GeneCentric
Stock and Other Ownership Interests - Bioclassifier; GeneCentric; Reveal Genomics
Consulting or Advisory Role - Bioclassifier; GeneCentric; NanoString Technologies; Reveal Genomics; Veracyte
Patents, Royalties, Other Intellectual Property - royalties from PAM50 breast cancer gene patent application, and from lung gene signature patent
 
Lisa A. Carey
Research Funding - Abbvie (Inst); NanoString Technologies (Inst); Novartis (Inst); Seagen (Inst); Syndax (Inst); Veracyte (Inst)
Patents, Royalties, Other Intellectual Property - Royalty-sharing agreement, investorship interest in licensed IP to startup company, Falcon Therapeutics, that is designing neural stem cell-based therapy for glioblastoma multiforme. (I)
(OPTIONAL) Uncompensated Relationships - Aptitude Health (Inst); AstraZeneca/Daiichi Sankyo (Inst); Eisai; Exact Sciences (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Sanofi (Inst)